[The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology].
Procedures, connected with extracorporal blood circulation--hemodialysis, hemosorption and plasmapheresis--were used in complex of treatment in 30 patients with various cardiovascular diseases. As an anticoagulant in 8 patients was used the preparation of low molecular heparine (Fraxiparine) produced by "Sanofi" (France) firm, and in 22-heparin, produced by "Polfa" (Poland). Ascertained advantages of Fraxiparine versus heparin were: possibility of single injection of preparation, the reducing of total dose magnitude, which is needed for one curative act conduction, lowering by 70% approximately the hemorrhagic complications rate.
Sirenko
Iu N
IuN
Sychev
O S
OS
Reĭko
M N
MN
Shchupak
M B
MB
Sidorenko
P I
PI
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use*; D016060:Sorption Detoxification / Q000379:methods*
D000925:Anticoagulants; D017762:Nadroparin; D006493:Heparin